We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
YGMZ | MingZhu Logistics Holdings Limited | 0.5566 | 0.2164 | 63.61% | 7,613,104 |
ELWS | Earlyworks Co Ltd | 3.24 | 1.11 | 52.11% | 1,086,184 |
FCUV | Focus Universal Inc | 0.2764 | 0.0444 | 19.14% | 77,552 |
INDP | Indaptus Therapeutics Inc | 2.77 | 0.40 | 16.88% | 3,685 |
CRGX | CARGO Therapeutics Inc | 22.00 | 3.00 | 15.79% | 3,476 |
GNPX | Genprex Inc | 3.58 | 0.47 | 15.11% | 223,793 |
IPDN | Professional Diversity Network Inc | 0.5799 | 0.0739 | 14.60% | 1,657 |
SISI | Shineco Inc | 2.29 | 0.29 | 14.50% | 6,969 |
QLI | Qilian International Holding Group Ltd | 0.899 | 0.099 | 12.38% | 852 |
ACON | Aclarion Inc | 0.3355 | 0.0355 | 11.83% | 829,110 |
JYD | Jayud Global Logistics Ltd | 0.76 | 0.08 | 11.76% | 24,783 |
NEW YORK and SHENZHEN, China, May 31, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced it has agreed to acquire Oxylus Global Inc ("Oxylus")., as part of its continued aggressive business diversification and growth acceleration strategy. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to be completed by the end of calendar year 2024.
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.
Brand Engagement Network Inc. (“BEN”) (Nasdaq: BNAI), an emerging provider of personalized customer engagement AI, today announced it has closed a private placement with existing investors of its common stock and warrants to purchase common stock in the aggregate amount of $4.95 million, providing the Company with increased financial flexibility to continue the development of its human-like, business-safe conversational AI assistants. Concurrently, BEN announced that Paul Chang has been promoted to Co-CEO, bringing his unique perspective to the leadership team alongside Co-CEO Michael Zacharski.
Quantum Corporation (Nasdaq: QMCO) ("Quantum" or the "Company"), a leader in solutions for AI and unstructured data, announced today it will release financial results for its full year fiscal 2024 ended March 31, 2024 on Monday, June 17, 2024 after markets close. Jamie Lerner, Chairman and CEO, and Kenneth Gianella, Chief Financial Officer, will host a conference call on the same day. Conference call information will follow in the coming days. The timing of the filing and conference call is in conjunction with the Company’s conclusion of its review of previously announced accounting matters.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,501.08 | -861.16 | -1.26% | 1.32T | 3,721,717,814 |
ETH | Ethereum | 3,762.44 | 15.31 | 0.41% | 451.7B | 2,180,327,979 |
USDT | Tether USD | 0.99899 | -0.00071 | -0.07% | 97.74B | 278,988,810 |
BNB | Binance Coin | 593.59 | -1.30 | -0.22% | 93.73B | 134,342,757 |
SOL | Solana | 165.58 | -1.24 | -0.74% | 73.06B | 812,146,500 |
STETH | stETH | 3,759.21 | 13.57 | 0.36% | 36.68B | 8,673,176 |
XRP | Ripple | 0.5176 | -0.0011 | -0.21% | 28.25B | 264,478,260 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 856,182,696 |
DOGE | Dogecoin | 0.15915 | -0.00033 | -0.21% | 22.77B | 269,130,709 |
TONCOIN | Wrapped TON Coin | 6.33 | -0.122888 | -1.90% | 22B | 44,490,468 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions